Alkyl amino acid derivatives useful as pharmaceutical agents
US6703522B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 21, 2002 |
| Grant date | Mar 9, 2004 |
| Priority date | — |
| Expiry date | Nov 21, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C233/83
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
GABA-related pro-drugs of the formula (III) are provided that when administered to humans or other mammals provide an increased duration of active compound in the plasma compared to compounds of corresponding structure in which labile groups are not present. The compounds are of the formula (III) In the above formula:P represents hydrogen or methyl;Q represents a labile amine- or amide-forming organic group that becomes removed in the human or animal body;R1 represents straight or branched C2-C6 alkyl, C3-C6 cycloalkyl or phenyl;R2 represents hydrogen or methyl; andR3 represents hydrogen, methyl or carboxyl; andR4 represents hydrogen or a labile ester-forming group selected from substituted and unsubstituted C1-C6 alkyl, benzyl and phenyl groups that become removed in the human or animal body. In the above formula when R1 is phenyl, R2, R3 and R4 are not simultaneously hydrogen. Pharmaceutically acceptable salts of any salt-forming compound within the above class are also included. The compounds may be used to treat a range of neurological conditions, e.g. epilepsy and pain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.